Bempedoic Acid (Nexletol) for Lowering LDL-Cholesterol
Date: April 6, 2020
Issue #:
1595Summary:
The FDA has approved the oral adenosine triphosphate-citrate
lyase (ACL) inhibitor bempedoic acid for
use alone (Nexletol– Esperion) and in a fixed-dose
combination with the cholesterol absorption inhibitor
ezetimibe(Nexlizet) as an adjunct to diet and maximally
tolerated statin therapy in adults with heterozygous
familial hypercholesterolemia (HeFH) or established
atherosclerotic cardiovascular disease (ASCVD) who
require additional lowering of LDL-cholesterol (LDL-C).
Bempedoic acid is the first ACL inhibitor to be approved
in the US.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: alirocumab Altoprev Atorvastatin bempedoic acid Cholesterol Cholestyramine Colesevelam Colestid Colestipol Crestor evolocumab Ezetimibe Ezetrol Fenofibrate Flolipid Fluvastatin Gemfibrozil icosapent ethyl Lescol Lipit Source Type: research
More News: Atorvastatin Calcium | Cardiology | Cardiovascular | Cholesterol | Crestor | Diets | Drugs & Pharmacology | Fenofibrate | Fluvastatin | Gemfibrozil | Heart | Lipitor | Nutrition | Rosuvastatin | Statin Therapy | Tricor | Vytorin | Welchol | Zetia | Zivast